Psychiatry and Neurology, Neurology · Seattle, WA
NPI
1326061748
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1100 9th Ave, Ms: X7-Neo
Seattle, WA, 98101
Phone (206) 223-6600
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
729 services
Medicare patients, 2024
147
Average age 67
Drug cost, 2024
$2.3M
1,296 prescriptions
Company payments, 2025
$8,563
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mariko Kita was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 93 times for 78 patients. In total Mariko Kita billed 729 services in 21 codes, and Medicare paid $29K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-11-20.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 93 | 78 | $13.89 | $1,291 |
| 99214 Office E&M - Established | Office | 88 | 65 | $87.77 | $7,723 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 74 | 52 | $12.75 | $944 |
| 99214 Office E&M - Established | Facility | 67 | 53 | $70.11 | $4,697 |
| 99215 Office E&M - Established | Facility | 34 | 30 | $105.21 | $3,577 |
| 36415 Venipuncture Blood Collection | Office | 20 | 15 | $8.65 | $173 |
| 99205 Office E&M - New | Facility | 14 | 14 | $145.71 | $2,040 |
By year: 2022 $26K for 649 services; 2023 $23K for 864 services; 2024 $29K for 729 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 20 | 15 | $8.65 | $173 |
Medicare prescription drug claims, 2024
In 2024, the drug Mariko Kita prescribed most often to Medicare patients was Baclofen, with 130 prescriptions and refills. In total Mariko Kita wrote 1,296 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 130 | 286 | 39 | $2,628 |
| Gabapentin Generic | 90 | 238 | 32 | $4,281 |
| Dalfampridine Er Dalfampridine | 77 | 143 | 14 | $36K |
| Kesimpta Pen Ofatumumab | 70 | 84 | 11 | $734K |
| Dimethyl Fumarate Generic | 66 | 87 | Under 11 | $153K |
| Tizanidine Hcl Generic | 48 | 110 | 15 | $1,447 |
| Copaxone Glatiramer Acetate | 40 | 41 | Under 11 | $252K |
| Glatiramer Acetate Generic | 39 | 44 | Under 11 | $110K |
| Tecfidera Dimethyl Fumarate | 39 | 43 | Under 11 | $338K |
| Oxcarbazepine Generic | 38 | 76 | 12 | $3,383 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 32 | 42 | Under 11 | $1,459 |
| Teriflunomide Generic | 31 | 41 | Under 11 | $68K |
| Sertraline Hcl Generic | 25 | 67 | Under 11 | $160 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 25 | 25 | Under 11 | $783 |
| Zolpidem Tartrate Generic | 24 | 51 | Under 11 | $317 |
Brand drugs: 234 claims; generic drugs: 1,062 claims; opioid claims: 99.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mariko Kita $8,563 ($8,563 in general payments such as food, travel and fees) from 2 companies. The largest payer was Biogen, Inc. with $8,563.
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. BIIB | 4 | $8,563 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.